A phase II study of nilotinib, a novel tyrosine kin ase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy.

被引：1
|
作者：
Giles, Francis
le Coutre, Philipp
Bhalla, Kapil
Rosti, Gianantonio
Ossenkopplele, G. J.
Alimena, Giuliana
Weitzman, Aaron
Rafferty, Teresa
Zheng, Ming
Kantarjian, Hagop
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Campus Virchow Klin, Berlin, Germany
[3] H Lee Moffitt Canc Ctr, Tampa, FL USA
[4] Univ Bologna Policlin, Azienda Osped, Bologna, Italy
[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] Univ Roma La Sapienza, Azienda Policlin Umberto, Rome, Italy
[7] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2170.2170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2170
引用
收藏
页码：615A / 616A
页数：2
相关论文
共 50 条
  • [41] A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to imatinib.
    Zwaan, Michel
    Stork, Linda C.
    Bertrand, Yves
    Gore, Lia
    Hijiya, Nobuko
    De Souza, Carmino
    Lee, Maria Lucia de Martino
    Bradley-Garelik, M. Brigid
    Kearns, Pamela
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Nilotinib in accelerated phase chronic myelogenous leukaemia (CML-AP) patients with imatinib-resistance or -intolerance: update of a phase 2 study
    Apperley, J.
    le Coutre, P.
    Giles, F. J.
    Ottmann, O. G.
    Larson, R. A.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 38 - 39
  • [43] Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study.
    Talpaz, M.
    Apperley, J. F.
    Kim, D. W.
    Silver, R. T.
    Bullorsky, E. O.
    Cheng, S.
    Iyer, M.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [44] Correlation of different responses to imatinib on survival of patients (pts) with chronic myelogenous leukemia (CML) in accelerated (AP) and blast phase (BP).
    Aoki, E
    Kantarjian, H
    O'Brien, S
    Rios, MB
    Ravandi, F
    Verstovsek, S
    Garcia-Manero, G
    Shan, JQ
    Cortes, J
    BLOOD, 2005, 106 (11) : 321A - 321A
  • [45] Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials.
    Silver, RT
    Talpaz, M
    Sawyers, CL
    Druker, BJ
    Hochhaus, A
    Schiffer, CA
    Guilhot, F
    Goldman, JM
    Smith, BD
    Mone, M
    Kranhnke, T
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 11A - 11A
  • [46] Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
    Ottmann, Oliver
    Saglio, Giuseppe
    Apperley, Jane F.
    Arthur, Christopher
    Bullorsky, Eduardo
    Charbonnier, Aude
    Dipersio, John F.
    Kantarjian, Hagop
    Khoury, Hanna Jean
    Kim, Dong-Wook
    Healey, Diane
    Strauss, Lewis
    Cortes, Jorge E.
    BLOOD CANCER JOURNAL, 2018, 8
  • [47] Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study.
    Hochhaus, A.
    Kantarjian, H.
    Baccarani, M.
    Cervantes, F.
    Facon, T.
    Goldberg, S.
    Erben, P.
    Countouriotis, A.
    Ezzedine, R.
    Druker, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 339S - 339S
  • [48] Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
    Oliver Ottmann
    Giuseppe Saglio
    Jane F. Apperley
    Christopher Arthur
    Eduardo Bullorsky
    Aude Charbonnier
    John F. Dipersio
    Hagop Kantarjian
    Hanna Jean Khoury
    Dong-Wook Kim
    Diane Healey
    Lewis Strauss
    Jorge E. Cortes
    Blood Cancer Journal, 8
  • [49] NILOTINIB IN CHRONIC MYELOGENOUS LEUKAEMIA IN BLAST CRISIS (CML-BC) PATIENTS WITH IMATINIB-RESISTANCE OR -INTOLERANCE: UPDATED PHASE 2 RESULTS
    Giles, J.
    Larson, R. A.
    Kantarjian, H. M.
    Le Coutre, P.
    Palandrini, F.
    Haque, A.
    Gallagher, N.
    Ottmann, O. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 46 - 46
  • [50] Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase, Accelerated Phase, or Blast Crisis: A Single- and Multiple-Dose, Open-Label Pharmacokinetic Study in Chinese Patients
    Zhou, Li
    Meng, Fanyi
    Yin, Ophelia
    Wang, Jianxiang
    Wang, Ying
    Wei, Yongqiang
    Hu, Pei
    Shen, Zhixiang
    CLINICAL THERAPEUTICS, 2009, 31 (07) : 1568 - 1575
12345